» Authors » William R Shanahan Jr

William R Shanahan Jr

Explore the profile of William R Shanahan Jr including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 6
Citations 250
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Kahan B, Stepkowski S, Kilic M, Katz S, Van Buren C, Welsh M, et al.
Transplantation . 2004 Sep; 78(6):858-63. PMID: 15385805
Background: ISIS 2302, an antisense oligonucleotide that inhibits the expression of human intercellular adhesion molecule (ICAM)-1, was evaluated in combination with a cyclosporine (CsA)-prednisone (Pred) regimen first in a phase...
2.
Leung D, Shanahan Jr W, Li X, Sampson H
Novartis Found Symp . 2004 Mar; 257:248-60. PMID: 15025403
Anaphylaxis represents the most extreme form of life-threatening allergic reactions. However, effective long-term therapies for this condition are not currently available. A number of potential approaches have proven effective in...
3.
Kuritzkes D, Jacobson J, Powderly W, Godofsky E, DeJesus E, Haas F, et al.
J Infect Dis . 2004 Jan; 189(2):286-91. PMID: 14722894
Background: We wished to determine the safety and anti-human immunodeficiency virus (HIV) type 1 activity of single doses of TNX-355, a humanized IgG4 anti-CD4 monoclonal antibody with potent activity against...
4.
Leung D, Shanahan Jr W, Sampson H
Ann Allergy Asthma Immunol . 2004 Jan; 91(6):515-7. PMID: 14700433
No abstract available.
5.
Leung D, Sampson H, Yunginger J, Burks Jr A, Schneider L, Wortel C, et al.
N Engl J Med . 2003 Mar; 348(11):986-93. PMID: 12637608
Background: Peanut-induced anaphylaxis is an IgE-mediated condition that is estimated to affect 1.5 million people and cause 50 to 100 deaths per year in the United States. TNX-901 is a...
6.
Maksymowych W, Blackburn Jr W, Tami J, Shanahan Jr W
J Rheumatol . 2002 Mar; 29(3):447-53. PMID: 11908555
Objective: To determine the safety of an antisense oligodeoxynucleotide to intercellular adhesion molecule-1 (ICAM-1) (ISIS 2302), administered in an intensive 4 week regimen with dose escalation; and to provide preliminary...